A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

NCT07456774 · Enrolling by invitation

Last updated 2026-05-28

This study is comparing how well adults in China with type 2 diabetes stick with Ozempic (a diabetes medication) compared to other diabetes drugs over time.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 100,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-02 · est. completion 2026-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07456774 ↗

Description as written by the study sponsor.

The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.

Main thing measured	Time to 3P major adverse cardiovascular events
Sponsor	Novo Nordisk A/S
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07456774 ↗